Boehringer Ingelheim Foundation supports research of Dr. Peng Wu

Boehringer Ingelheim Foundation supports research of Dr. Peng Wu

Dr. Peng Wu receives 90.000 Euros from the Boehringer Ingelheim Foundation for his research on the degradation of mRNA

July 15, 2021

The Boehringer Ingelheim Foundation is funding the research of Dr. Peng Wu, group leader at the Chemical Genomics Centre of the Max Planck Society, with an Exploration Grant. He will receive approx. 90.000 Euros to explore new lines of research in his project “Small molecules modulate the RNA-binding protein-mediated degradation of mRNA”.

Dr. Peng Wu is an independent group leader at the CGC since 2018. His research work focuses on the development of novel small molecule-based chemical modulators to manipulate pervasive protein-RNA interactions. With his new project he aims to target the RNA-binding proteins that recognize the mRNA modifications for the identification of small-molecule inhibitors and activators. Such small molecules will be evaluated as potential hits for tools to probe the regulatory network involving these RNA-binding proteins that mediate mRNA-degradation and as hits for therapeutics for the treatment of human diseases such as in neurological disorders and viral infections that are associated with dysregulation of such RNA-binding proteins. 

About the Boehringer Ingelheim Foundation

The Boehringer Ingelheim Foundation is a legally independent, non-profit foundation committed to the promotion of the medical, biological, chemical, and pharmaceutical sciences. It was established in 1977 by Hubertus Liebrecht, a member of the shareholder family of the Boehringer Ingelheim company. With the Perspectives Programme Plus 3 and its Exploration Grants, the foundation supports independent junior group leaders.

Go to Editor View